 |
|
|
| |
Long-term Safety Profile of Tenofovir Alafenamide
in Chronic Hepatitis B Patients: Final 8-Year Results of 2 Phase 3 Studies
|
| |
| |
EASL 2023 June 21-24 Vienna
EASL 2023 - Long-term Efficacy of Tenofovir Alafenamide in HBeAg-positive and HBeAg-negative Chronic Hepatitis B Patients Treated for up to 8 Years in 2 Phase 3 Studies - (06/26/22)
Young-Suk Lim1, Henry Lik Yuen Chan2, Kosh Agarwal3, Patrick Marcellin4, Maurizia R Brunetto5, Wan-Long Chuang6, Harry LA Janssen7,8, Scott K Fung9, Namiki Izumi10, Maciej S Jablkowski11, Frida Abramov12, Hongyuan Wang12,
Leland J Yee12, John F Flaherty12, Calvin Pan13, Dr Shalimar14, Wai-Kay Seto15, Edward J Gane16, Maria Buti17,18
The Aging Kidney: physiological changes, Weinstein JR, Adv Chronic Kidney Dis., 2010
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901622/
|
| |
|
|
|
|
|
